Completed PHASE1 INTERVENTIONAL 1-arm NCT05320861

Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects

A Single Dose Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]SJP-0008 in Healthy Male Subjects After an Oral Dose

Sponsor: Quotient Sciences

Conditions Healthy Volunteers

Interventions [14C]SJP-0008

Updated 3 times since 2022 Last updated: Apr 1, 2022 Started: Sep 24, 2021 Primary completion: Nov 2, 2021 Completion: Nov 2, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Quotient Sciences and has accumulated 3 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Quotient Sciences
Senju Pharmaceutical Co., Ltd.

Data source: Senju Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom